Roundtable Discussion: Extending the Lifecycle of Oligonucleotide Therapeutics: Strategic Considerations to Maximize Product Value Beyond Approval
Key questions to be addressed:
- Defining lifecycle management strategies to extend product longevity and delay generic entry while maintaining regulatory compliance
- Leveraging CMC changes and control strategy evolution to support product differentiation and sustain competitive advantage
- Aligning scientific, regulatory, and commercial priorities to maximize product value across late-stage development and commercialization
- Identifying key risks and trade-offs when implementing lifecycle strategies, including comparability, regulatory burden, and market impact